抗凝药比伐卢定在冠状动脉介入领域中的应用进展

The advance in research during percutaneous coronary intervention of anticoagulant drug bivalirudin

比伐卢定(bivalirudin)是一种新型直接凝血酶抑制剂,2000年被美国食品药品监督管理局批准应用于临床。比伐卢定是水蛭素的衍生物,通过抑制凝血酶的活性位点而起效,国外将其与其他常用抗凝药进行了比较研究,认为比伐卢定可以作为普通肝素和糖蛋白GPⅡb/Ⅲa受体阻滞剂的替代药物用于手术过程中的抗凝治疗。现综述比伐卢定的药理学特点及其在经皮冠状动脉介入治疗、肝素诱导的血小板减少症及对血小板功能的影响等方面的临床研究进展。

Bivalirudin, as a direct inhibitor of thrombin was approved by US Food and Drug Administration in 2000. It is an analogue of hirudin that can inhibit the active site of thrombus. It is reposed by overseas studies that as compared with other anticoagulants, bivalirudin can be a substitute for heparin or glycoprotein (GP) Ⅱb/Ⅲa inhibitors in patients undergoing invasive treatment.